Overview

A Pilot Study of Technetium [99Tc] Methylene Diphosphonate in the Treatment of Psoriatic Arthritis

Status:
Completed

Trial end date:
2021-07-01

Target enrollment:

Participant gender:

Summary

This study is aim to evaluate the efficacy and safety of technetium [99Tc] methylene diphosphonate (99Tc-MDP, trade name: Yunke) in the treatment of psoriatic arthritis.

Phase:

Phase 4

Details

Lead Sponsor:

Peking Union Medical College Hospital

Collaborator:

Chengdu Yunke Pharmaceutical Co., Ltd.

Treatments:

Diphosphonates
Methylene diphosphonate